Complete Conference Management 29th Annual Heart Failure 2025

Advanced Heart Failure Management, Cardiovascular Prevention & Contemporary Therapeutic Updates

The Complete Conference Management 29th Annual Heart Failure 2025 – An Update on Therapy Symposium is a comprehensive cardiovascular education program designed to provide clinicians with the latest evidence-based advances in the prevention, diagnosis, and management of heart failure. This annual symposium brings together leading cardiovascular experts to review emerging therapies, guideline updates, and practical management strategies for patients with acute and chronic heart failure.

Through expert-led lectures, case-based discussions, and interactive faculty sessions, participants gain valuable insights into modern heart failure care, including heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), acute decompensated heart failure, cardiorenal syndrome, atrial fibrillation, pulmonary hypertension, obesity-related heart failure, amyloidosis, and hypertrophic cardiomyopathy.

The program emphasizes real-world clinical application, helping clinicians optimize patient outcomes through contemporary pharmacologic, interventional, and multidisciplinary treatment approaches.

Product Details

• Format: 19 Videos + 19 Audios + 19 Subtitle Files (.VTT) + 21 PDFs
• Total Size: 6.7 GB
• Course Year: 2025
• Access: On-Demand
• Event Type: Hybrid Conference (In-Person & Virtual)

Program Overview

This symposium provides a practical and comprehensive review of modern cardiovascular medicine with a primary focus on heart failure management.

Major areas of focus include:

• Heart failure with reduced ejection fraction (HFrEF)
• Heart failure with preserved ejection fraction (HFpEF)
• Acute decompensated heart failure
• Hypertension
• Hyperlipidemia
• Atrial fibrillation
• Cardiorenal syndrome
• Valvular heart disease
• Pulmonary arterial hypertension
• Cardiac amyloidosis
• Hypertrophic cardiomyopathy
• Obesity and heart failure
• Advanced cardiovascular therapies

Participants gain evidence-based knowledge that can be immediately incorporated into clinical practice.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Apply updated guideline-directed medical therapy for heart failure.
• Implement contemporary treatment strategies for HFrEF and HFpEF.
• Evaluate and manage acute decompensated heart failure.
• Integrate current hypertension and lipid management guidelines into cardiovascular care.
• Address the complexities of heart failure in patients with kidney disease.
• Manage atrial fibrillation in heart failure populations.
• Assess catheter-based interventions for valvular heart disease.
• Develop individualized treatment plans for patients with amyloidosis, hypertrophic cardiomyopathy, obesity-related heart failure, and pulmonary arterial hypertension.

Core Topics Covered

Heart Failure with Reduced Ejection Fraction (HFrEF)

A major focus of the symposium is modern management of HFrEF.

Topics include:

• Guideline-directed medical therapy (GDMT)
• SGLT2 inhibitors
• ARNI therapy
• Beta-blockers
• Mineralocorticoid receptor antagonists
• Device therapy considerations
• Long-term disease management

Faculty review the latest evidence supporting improved patient outcomes.

Heart Failure with Preserved Ejection Fraction (HFpEF)

Participants explore evolving treatment strategies for HFpEF, including:

• Diagnostic evaluation
• Phenotype-based management
• SGLT2 inhibitor therapy
• Comorbidity optimization
• Exercise and lifestyle interventions

Current evidence and guideline recommendations are discussed in depth.

Acute Decompensated Heart Failure

Dedicated sessions cover:

• Hospital management strategies
• Diuretic optimization
• Hemodynamic stabilization
• Volume assessment
• Transition-of-care planning
• Readmission prevention

Practical approaches for managing critically ill patients are emphasized.

Heart Failure & Kidney Disease

The conference examines the complex relationship between cardiovascular and renal disease.

Topics include:

• Cardiorenal syndrome
• Renal protection strategies
• Medication management
• Fluid balance optimization
• Chronic kidney disease in heart failure

Participants learn how to improve outcomes in this challenging patient population.

Atrial Fibrillation in Heart Failure

Faculty review:

• Rhythm versus rate control
• Anticoagulation strategies
• Catheter ablation
• Device-based therapies
• Integrated management approaches

Special attention is given to improving quality of life and reducing cardiovascular events.

Valvular Heart Disease & Structural Interventions

Topics include:

• Transcatheter valve therapies
• Mitral valve interventions
• Tricuspid valve disease
• Structural heart procedures
• Patient selection and outcomes

The course highlights advances in minimally invasive cardiovascular care.

Hypertension & Hyperlipidemia

Participants receive updates on:

• New hypertension guidelines
• Resistant hypertension
• Lipid-lowering therapies
• PCSK9 inhibitors
• Cardiovascular risk reduction

Faculty discuss practical implementation in daily practice.

Cardiac Amyloidosis

Sessions explore:

• Early diagnosis
• Cardiac imaging
• Disease-modifying therapies
• Prognostic assessment
• Long-term management

The symposium reviews recent advances that have transformed care for amyloidosis patients.

Hypertrophic Cardiomyopathy

Topics include:

• Diagnostic evaluation
• Risk stratification
• Medical therapy
• Novel pharmacologic treatments
• Sudden cardiac death prevention

Experts discuss contemporary management approaches.

Obesity & Heart Failure

Participants learn about:

• Obesity-related cardiovascular disease
• Weight management strategies
• GLP-1 receptor agonists
• Metabolic health optimization
• Impact on heart failure outcomes

Emerging therapies and clinical evidence are reviewed.

Pulmonary Arterial Hypertension

The conference reviews:

• Diagnostic pathways
• Risk assessment
• Pharmacologic therapies
• Right heart failure management
• Advanced treatment options

Participants gain practical updates on managing complex pulmonary vascular disease.

Educational Features

✔ Comprehensive Heart Failure Review

✔ Evidence-Based Guideline Updates

✔ HFrEF & HFpEF Management

✔ Cardiorenal Syndrome Education

✔ Structural Heart Disease Updates

✔ Hypertension & Lipid Management

✔ Advanced Cardiomyopathy Sessions

✔ Interactive Expert Discussions

Target Audience

This course is ideal for:

• Cardiologists
• Internal Medicine Physicians
• Primary Care Physicians
• Heart Failure Specialists
• Cardiovascular Fellows
• Nurse Practitioners
• Physician Assistants
• Pharmacists
• Cardiac Nurses
• Advanced Practice Providers

Why This Course Stands Out

✔ Dedicated exclusively to modern heart failure management

✔ Covers both acute and chronic heart failure

✔ Strong emphasis on practical clinical decision-making

✔ Reviews latest cardiovascular guidelines and therapies

✔ Includes cardiorenal, arrhythmia, and structural heart disease updates

✔ Addresses obesity, amyloidosis, and hypertrophic cardiomyopathy

✔ Multidisciplinary cardiovascular education

✔ Designed for immediate application in clinical practice

Clinical & Educational Value

The Complete Conference Management 29th Annual Heart Failure 2025 symposium delivers a comprehensive review of contemporary heart failure and cardiovascular medicine. Through expert-led education covering HFrEF, HFpEF, cardiorenal disease, arrhythmias, valvular interventions, pulmonary hypertension, and advanced heart failure therapies, participants gain practical strategies to improve outcomes for patients across the spectrum of cardiovascular disease.

+ Topics:

• 7:00-8:00am Registration/Visit Exhibits
• 7:45-8:45 ProductTheatre I – Breakfast – Non-CME hATTR Progression: Addressing Polyneuropathy Supported by: AstraZeneca Speaker: DmitryYaranov, MD
• 8:45-8:55 Introduction to the 29th Annual Symposium: Heart Failure 2025 – An Update on Therapy Uri Elkayam, MD
• SESSION I 8:55-9:15 Hyperlipidemia: An Update on Non-Statin Therapy PamTaub, MD
• 9:15- 9:35 Evolving Strategies for the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors,When and How to UseThem Michelle M. Kittleson, MD
• 9:35-9:55 Treating Congestion and Optimizing GDMP in the Hospitalized Patient with ADHF Maria Rosa Costanzo, MD
• 9:55-10:15 Contemporary DrugTherapy for Patients with Heart Failure and Reduced Ejection Fraction Akshay Desai, MD
• 10:15-10:35 Visit Exhibits/Break
• SESSION II 10:35-11:00 KEYNOTE LECTURE Advances In GeneTherapy ForTreating PatientsWith Cardiomyopathy Barry Greenberg, MD
• 11:00-11:20 How Do I Optimize Heart Failure Medications for Patients with Chronic and End Stage Kidney Disease? Maria Rosa Costanzo, MD
• 11:20-11:40 The Contemporary Approach to the Management of Cardiogenic Shock Nir Uriel, MD
• 11:40-11:55 HFpEF: Diagnostic Challenges and Pitfalls Uri Elkayam, MD
• 11:55-12:15 Advances in Pharmacologic and Nonpharmacological Management of HFpEF Akshay Desai, MD
• 12:15-1:15 ProductTheatre II – Luncheon – Non-CME Introduction to AMVUTTRA® (vutrisiran) Supported by: Alnylam Pharmaceuticals Speaker: Marcus Anthony Urey, MD
• 1:15-1:20 Break
• 1:20-1:50 Industry Session – Non-CME Rethinking Hyperkalemia Management in Patients on RAAS InhibitorTherapy Supported by: AstraZeneca Speaker: Ashish Brahmbhatt, PharmD
• 1:50-1:55 Break
• SESSION III 1:55-2:15 Closing the Knowledge Gap On Diagnosis AndTreatment Of Implantable Cardiac Device Infection In Heart Failure Ulrika Birgersdotter-Green, MD
• 2:15-2:35 Tricuspid Regurgitation: Prevalence, Prognostic Implications and Emerging Therapy Steven Burstein, MD
• 2:35-2:55 Management of Atrial Fibrillation in Patients Across the Spectrum of Heart Failure Anil Bhandari, MD
• 2:55-3:15 Anti-Obesity Medications in Patients with Heart Failure: Current Evidence and Practical Guidance Amanda R. Vest, MBBS, MPH
• 3:15-3:35 Break/Visit Exhibits
• SESSION IV 3:35-3:50 Beyond MedicalTherapy – Carotid Baroreceptor Stimulation and Cardiac Contractility Modulation Michael Fong, MD
• 3:50-4:10 Finerenone – A New Option for the Management of Heart Failure and Kidney Disease: Results of ClinicalTrials and Implications forTherapy Uri Elkayam, MD
• 4:10-4:30 What is New in the Management of Hypertension – Review of the 2024 ESC Guidelines Vito Campese, MD
• 4:30-4:50 ATTR Amyloidosis: Current and Emerging Management Strategies Mazen Hanna, MD
• 4:50-5:10 Pulmonary Arterial Hypertension: Introduction of NewTherapy Ron Oudiz, MD
• 5:10-5:30 The Potential Use Of AI InThe Diagnosis And Management Of Heart Failure Nir Uriel, MD
• 5:30pm Adjourn